Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: Two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days

Journal of Women's Health and Gender-Based Medicine

Volumn 9, Issue 4, 2000, Pages 421-429

  Upmalis, David H ^a   Cone, Frederick L ^a   Lamia, Cathleen A ^a   Reisman, Howard ^b   Rodriguez Gomez, Guillermo ^c   Gilderman, Larry ^d   Bradley, Lynn ^e  

^a Advanced Care Products ^*  (United States)

^b Atlanta North Gynecology   (United States)

^c Inst Costarricense Invest y E   (Costa Rica)

^d Univ of Clin Res Assoc Inc   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; MICONAZOLE; MICONAZOLE NITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME; VAGINA CANDIDIASIS;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; MICONAZOLE; MIDDLE AGED; PATIENT SATISFACTION; SINGLE-BLIND METHOD; SOUTH AMERICA; TREATMENT OUTCOME; UNITED STATES; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 0034049003     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/15246090050020745     Document Type: Article

References (10)

1. Paavonen J, Stamm WE. Lower genital tract infections in women. Infect Dis Clin North Am 1987;1:179.
2. Sobel JD. Pathophysiology of vulvovaginal candidiasis. J Reprod Med 1989;34(Suppl 8):572.
3. Fleury FJ. Adult vaginitis. Clin Obstet Gynecol 1981;24:407.
4. Berg AO, Heidrick FE, Fihn SD, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA 1984;251:620.
5. Tobin MJ. Vulvovaginal candidiasis: Topical vs. oral therapy. Am Fam Physician 1995;51:1715.
6. Lynch ME, Sobel JD, Fidel PL. Role of antifungal drug resistance in the pathogenesis of recurrent vulvo-vaginal candidiasis. J Med Vet Mycol 1996;34:337.
7. Nixon SA. Vulvovaginitis: The role of patient compliance in treatment success. Am J Obstet Gynecol 1991;165:1207.
8. Stevens RE, Konsil J, Silletti SL, Upmalis DH, Cone FL. Department of Pharmacokinetics/Pharmacodynamics, Phoenix International Life Sciences Inc., Cincinnati, OH, and Clinical Affairs, Advanced Care Products, North Brunswick, NJ. Bioavailability study of a 1200-mg miconazole nitrate vaginal ovule in healthy female adults [abstract 3400]. In: PharmSci Supplement. San Francisco, CA: American Association of Pharmaceutical Scientists, 1998;1:S-479.
9. Stevens RE, Konsil J, Silletti SL. Department of Pharmacokinetics/Pharmacodynamics, Phoenix International Life Sciences, Inc., Cincinnati, OH. A unique perspective to optimize study design using simulation to estimate drug absorption of a new 1-day 1200-mg miconazole nitrate vaginal ovule in normal volunteers [abstract 2057]. In: PharrnSci Supplement. San Francisco, CA: American Association of Pharmaceutical Scientists, 1998;1:S-164.
10. Sobel JD, Faro S, Force RW, Foxman B, et al. Vulvo-vaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.